BRODALUMAB

Course overview

BRODALUMAB IS A MONOCLONAL ANTIBODY APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN ADULT PATIENTS WHO HAVE FAILED TREATMENT WITH TOPICAL AND OTHER SYSTEMIC THERAPY. IN ADDITION TO PLAQUE PSORIASIS, BRODALUMAB HAS BEEN EXPLORED AS A POTENTIAL TREATMENT FOR OTHER AUTO-INFLAMMATORY DISEASES, INCLUDING PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS. THIS ACTIVITY REVIEWS THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, TOXICITY, DOSING, PHARMACODYNAMICS, AND MONITORING OF BRODALUMAB, PERTINENT FOR MEMBERS OF THE INTERPROFESSIONAL TEAM FOR THE TREATMENT OF PATIENTS WITH INDICATED INFLAMMATORY PATHOLOGIES.